Blood
Articles in this Issue
Longitudinal genomic analysis of clonal hematopoiesis and tumor-associated mutations in acute myeloid leukemia
Abstract [INTRODUCTION] Clonal hematopoiesis (CH) refers to a clonal expansion of blood cells due to a genetic mutation in hematopoietic ste...
CAR T-cell therapy in secondary CNS lymphomas: A real-world study from the descar-t registry
Abstract Introduction Lymphomas with central nervous system (CNS) involvement were excluded from major clinical trials o...
Outcomes of immune checkpoint inhibitor therapy in Hodgkin lymphoma with and without pre-existing autoimmune disease: A real-world propensity-matched cohort analysis
Abstract Background: Immune checkpoint inhibitors (ICIs) have become a standard of care in relapsed or refractory Hodgkin lymphoma (HL), off...
Ultra-deep whole-genome sequencing of cell-free DNA recovers most bone marrow-derived mutations in newly diagnosed multiple myeloma
Abstract Introduction Cell-free DNA whole-genome sequencing (cfWGS) offers a non-invasive alternative to molecular profiling of multiple mye...
Optimizing letermovir timing: Day +5 to +8 post haplo-HSCT minimizes EBV dnaemia without compromising CMV prophylaxis
Abstract Background The era of Letermovir (LTV) has reshaped CMV prophylaxis and treatment following allogeneic HSCT, with its efficacy in r...
Identification of SHMT2 and ADAM28 as potential mediators of NFIC pro-growth effects in AML
Abstract Acute myeloid leukemia (AML) is a heterogeneous group of hematological malignancies characterized by the accumulation of clonal, ab...
Impact of conditioning intensity on outcomes after unrelated donor hematopoietic cell transplantation using posttransplant cyclophosphamide-based GVHD prophylaxis
Abstract Background: Reduced-intensity or non-myeloablative (RIC/NMA) conditioning is commonly used in allogeneic hematopoietic cell transpl...
Spatially decoding genotype-associated epigenetic landscapes in human lymphoma FFPE tissues via epi-Patho-DBiT
Abstract Chromatin organization within the cell nucleus governs the epigenetic regulation of diverse cellular functions and is tightly contr...
C1-INH and atiii inhibit vaso-occlusion and vascular inflammation in sickle cell disease mice
Abstract Background. C1 esterase inhibitor (C1-INH) is a serine protease inhibitor (serpin) in plasma that regulates the complement and cont...
Bone marrow CD57+ LGL cells comprised of NK and CD8 T cells drive bone marrow failure in Myelodysplastic Syndromes
Abstract Background: Autoimmune phenomena occur in 20-50% of patients with myelodysplastic syndromes (MDS), exacerbating...
METTL3 inhibition disrupts R-loop homeostasis and activates the cgas-sting pathway in Acute Myeloid Leukemia
Abstract Acute myeloid leukemia (AML) is an aggressive blood cancer with poor prognosis. Heterogeneity within its drivers and low cure rate...
A single-cell co-expression score of MYC and BCL2 identifies high-risk BCR-addicted DLBCL benefiting from polatuzumab vedotin in the POLARIX trial
Abstract Introduction: Double Expressor Lymphoma (DEL) refers to diffuse large B-cell lymphoma (DLBCL) with overexpression of the oncogenes M...
Vaccination targeting azacytidine-induced neoantigens in the C1498 murine AML model
Abstract Hypomethylating agents, including azacytidine (AZA), are a cornerstone of frontline acute myeloid leukemia (AML) therapy. AZA inhib...
Dexamethasone dose intensity does not improve 6-month responses in newly diagnosed multiple myeloma and may contribute to hyperglycemia
Abstract Introduction The role of dexamethasone in newly diagnosed multiple myeloma (NDMM) is increasingly being challenged given that highe...
Impact of NRAS and/or KRAS mutations on post-transplant outcomes in Acute Myeloid Leukemia: A study on behalf of EBMT-ALWP
Abstract Background: NRAS, and/or KRAS mutations are identified in 10–15% of patients diagnosed with acute myeloid leukemia (AML). While the...
Trial in progress: QUINTESSENTIAL—a phase 2 study of arlocabtagene autoleucel (arlo-cel) in patients with relapsed/refractory multiple myeloma (RRMM)
Abstract Background and Significance: Limited treatment options exist for patients (pts) with RRMM who have been exposed to 3 or more drug cl...
Time-limited pirtobrutinib, venetoclax, and obinutuzumab combination in first-line chronic lymphocytic leukemia
Abstract Introduction: Combined therapy with covalent BTK inhibitors (BTKi) and BCL2 inhibitor +/- CD20 mAb leads to high rates of undetecta...
Test characteristics of end-of-treatment PET scans in diffuse large b-cell lymphoma in a population-level cohort
Abstract Introduction: First-line treatment of diffuse large B-cell lymphoma (DLBCL) consists of chemoimmunotherapy followed by end-of-treat...
Maintenance therapy following chimeric antigen receptor T-cell therapy in relapsed and refractory multiple myeloma: An exploratory case series evaluating feasibility and safety in a real-world setting
Abstract Introduction: Chimeric antigen receptor (CAR) T-cell therapy has demonstrated remarkable efficacy in patients with relapsed and ref...
Factors impacting treatment choice with a CD38 antibody, immunomodulator, proteasome inhibitor, and dexamethasone in first line multiple myeloma patients: A real-world US study
Abstract Background: In 2023, the NCCN first listed a quadruplet (quad) regimen of a CD38 Antibody, Immunomodulator, Proteasome Inhibitor, an...
Myeloma mortality trends in the United States (Excluding Puerto Rico), 1999–2021, and future projections using ARIMA modeling and machine learning
Abstract Myeloma, including multiple myeloma, is the most prevalent plasma cell neoplasm in the United States and represents a significant c...
Antibody-mediated in-vitro antigen removal from red blood cells prior to transfusion enhances survival and reduces alloimmunization
Abstract Background: While transfusion can be beneficial for many patient populations, the formation of red blood cell (RBC) alloantibodies...
Antidepressant agent use and risk of bleeding in patients with cancer: Results from the vienna CAT-bled study
Abstract Background: The blood coagulation system is dysregulated in patients with cancer. While the risk of thrombosis is well established,...
Deletion of TRAF3 and CYLD and NIK amplification activates NF-kb signalling and drives resistance to T cell based therapies in multiple myeloma by suppressing T cell activity
Abstract Patients with Multiple Myeloma (MM) receiving adaptive T cell therapies such as chimeric antigen receptor (CAR) T cells and T cell...
Phase 3 study (inMIND) of tafasitamab plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma: Clinical characteristics and outcomes of patients receiving second-line treatment
Abstract Introduction: In patients (pts) with follicular lymphoma (FL) durability of response in second-line (2L) therapy is important, as p...